The rising tide of trial transparency
This article was originally published in Scrip
The tide seems to be turning in the clinical trial disclosure debate, and not in the industry's favor. True, the "principles for responsible data sharing" drawn up last year by industry bodies EFPIA and PhRMA came into effect on 1 January, and several companies, now including Sanofi, have accordingly announced policies in line with those principles.
You may also be interested in...
Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.
The UK government says it will begin a consultation on a future falsified medicines scheme for Great Britain within a year after the passage of new legislation on medicines and medical devices. Moves are also under way to ensure the smooth supply of medicines from GB to Cyprus, Ireland, Malta and Northern Ireland.
The team behind Russia’s first COVID-19 vaccine has asked for scientific advice from EU drug regulators in view of a possible submission for marketing authorization.